NEWPORT INTERNATIONAL JOURNAL OF SCIENTIFIC AND EXPERIMENTAL SCIENCES (NIJSES)

Volume 7 Issue 2 Page 131-134, 2026

ONLINE ISSN:2992-5819 PRINT ISSN:2992-6149

Open Access

https://doi.org/10.59298/NIJSES/2026/72.131134

SGLT2 Inhibitors in Type 2 Diabetes: Cardiorenal Protection Mechanisms and Clinical Outcomes

Nakawungu Catherine

Department of Pharmaceutical Microbiology and Biotechnology Kampala International University Uganda
Email: catherine.nakawungu@studwc.kiu.ac.ug

ABSTRACT

Type 2 diabetes mellitus was a complex metabolic disorder associated with a high burden of cardiovascular and renal complications, which remained the leading causes of morbidity and mortality despite advances in glycemic control strategies. Sodium glucose cotransporter 2 inhibitors emerged as a novel class of antidiabetic agents that extended therapeutic benefits beyond glucose lowering, particularly in cardiovascular and renal protection. The purpose of this review was to critically examine the biochemical, physiological, and clinical mechanisms through which SGLT2 inhibitors conferred cardiorenal benefits in individuals with Type 2 diabetes. A narrative literature synthesis of experimental studies, mechanistic research, and large-scale randomized clinical trials was employed to develop this review. Evidence indicated that SGLT2 inhibitors exerted multifaceted protective effects, including modulation of renal hemodynamics, improvement in myocardial energetics, reduction of systemic inflammation, and favorable alterations in metabolic and neurohormonal pathways. Clinical trials consistently demonstrated significant reductions in heart failure hospitalization, progression of chronic kidney disease, and cardiovascular mortality. SGLT2 inhibitors represented a paradigm shift in the management of Type 2 diabetes by addressing both metabolic control and end-organ protection. Their integration into routine clinical practice was strongly supported, with continued research warranted to refine patient selection and explore long-term outcomes across diverse populations.

Keywords: Type 2 diabetes mellitus, SGLT2 inhibitors, Cardiorenal protection, Cardiovascular outcomes, Diabetic kidney disease.

INTRODUCTION

Type 2 diabetes mellitus is a global public health challenge characterized by chronic hyperglycemia resulting from insulin resistance, impaired insulin secretion, or both [1, 2]. Beyond disturbances in glucose metabolism, the disease is strongly associated with cardiovascular disease and chronic kidney disease, which collectively account for the majority of diabetes related morbidity and mortality [3]. Traditional glucose-lowering therapies have demonstrated limited efficacy in reducing these complications, highlighting the need for therapeutic strategies that target both metabolic and organ-specific pathways.

Sodium glucose cotransporter 2 inhibitors have transformed the therapeutic landscape of Type 2 diabetes by introducing a mechanism of action independent of insulin [4, 5]. By inhibiting renal glucose reabsorption in the proximal tubules, these agents promote glycosuria and modest reductions in blood glucose levels. However, growing evidence suggests that their clinical benefits extend far beyond glycemic control. Large cardiovascular and renal outcome trials have consistently demonstrated reductions in heart failure events, slowing of kidney disease progression, and improved survival, even in patients without diabetes.

Despite the expanding clinical use of SGLT2 inhibitors [6], the precise biochemical and physiological mechanisms underlying their cardiorenal protective effects remain an area of active investigation. Understanding these mechanisms is critical for optimizing therapeutic application and guiding future research. This review addresses this knowledge gap by examining the molecular and systemic pathways involved in SGLT2 inhibition, the renal and cardiovascular adaptations that follow, and the clinical outcomes observed in major trials. Each section of the article explores a distinct yet interconnected aspect of SGLT2 inhibitor action, culminating in an integrated perspective on their role in modern diabetes care. The purpose of this review is to synthesize current evidence and provide a comprehensive framework for understanding the cardiorenal benefits of SGLT2 inhibitors in Type 2 diabetes.

Biochemical and Molecular Basis of SGLT2 Inhibition

Sodium glucose cotransporter 2 is a high-capacity, low-affinity transporter located predominantly in the proximal renal tubules, where it is responsible for reabsorbing approximately 90 percent of filtered glucose [7]. Inhibition of this transporter leads to increased urinary glucose excretion, resulting in reductions in plasma glucose levels independent of insulin secretion or action. This mechanism is particularly advantageous in Type 2 diabetes, where insulin resistance and beta cell dysfunction limit the efficacy of traditional therapies.

At the molecular level, SGLT2 inhibition alters cellular energy handling by promoting a mild caloric loss and shifting substrate utilization toward increased lipid oxidation and ketone body production [8]. These metabolic adaptations have been proposed to enhance myocardial and renal energetic efficiency. Additionally, reduced intracellular glucose availability in renal tubular cells may attenuate glucotoxicity, oxidative stress, and proinflammatory signaling pathways.

Emerging evidence also suggests that SGLT2 inhibitors influence signaling pathways involved in cellular senescence, autophagy, and mitochondrial function [9]. Activation of adenosine monophosphate-activated protein kinase and suppression of mechanistic target of rapamycin signaling have been observed, promoting cellular resilience and metabolic homeostasis. These molecular effects extend beyond the kidney, influencing vascular endothelial function and myocardial metabolism. Collectively, the biochemical actions of SGLT2 inhibitors provide a mechanistic foundation for their systemic effects. By targeting fundamental metabolic and signaling pathways, these agents exert protective influences that are not solely attributable to glucose lowering, thereby supporting their role as disease-modifying therapies [10].

Renal Hemodynamic and Metabolic Mechanisms of Nephroprotection

The kidney is a central target organ for the protective effects of SGLT2 inhibitors. In Type 2 diabetes, increased proximal tubular glucose and sodium reabsorption lead to reduced sodium delivery to the macula densa [11], resulting in afferent arteriolar dilation and intraglomerular hypertension. This maladaptive response accelerates glomerular injury and albuminuria.

SGLT2 inhibitors restore tubuloglomerular feedback by increasing sodium delivery to the distal nephron, promoting afferent arteriolar constriction and normalization of intraglomerular pressure [12]. This hemodynamic correction reduces hyperfiltration and mitigates structural damage to the glomerulus. Clinically, this mechanism is reflected by an initial modest decline in estimated glomerular filtration rate, followed by long-term stabilization of renal function.

In addition to hemodynamic effects, SGLT2 inhibitors reduce renal oxygen consumption by decreasing tubular workload [13]. Improved renal cortical oxygenation may attenuate hypoxia-induced fibrosis and inflammation, key drivers of chronic kidney disease progression. Furthermore, these agents have been shown to reduce albuminuria, an independent predictor of cardiovascular and renal risk. Metabolic effects, including reduced uric acid levels and improved lipid handling, further contribute to nephroprotection. Anti-inflammatory and antifibrotic actions have also been reported, mediated in part through suppression of proinflammatory cytokines and inhibition of transforming growth factor beta signaling. Together, these mechanisms position SGLT2 inhibitors as powerful agents for preserving renal structure and function in Type 2 diabetes.

Cardiovascular Protective Mechanisms of SGLT2 Inhibitors

Cardiovascular disease remains the leading cause of death in individuals with Type 2 diabetes, necessitating therapies that address cardiac risk directly [14]. SGLT2 inhibitors have demonstrated robust cardiovascular benefits, particularly in reducing heart failure-related outcomes. Several complementary mechanisms have been proposed to explain these effects.

Hemodynamically, SGLT2 inhibitors induce mild natriuresis and osmotic diuresis, leading to reductions in preload and afterload without activating sympathetic pathways [15]. This contrasts with traditional diuretics and may explain the early separation of event curves observed in heart failure trials. Reductions in blood pressure and arterial stiffness further contribute to cardiovascular protection.

At the myocardial level, enhanced ketone body availability provides an efficient energy substrate for the failing heart, improving cardiac energetics and contractile function. SGLT2 inhibitors also reduce myocardial inflammation, oxidative stress, and fibrosis, thereby preserving cardiac structure and function [16]. Vascular benefits include improved endothelial function, reduced oxidative stress, and favorable effects on atherosclerotic plaque stability.

Additionally, modulation of adipokine secretion and reduction in visceral adiposity contribute to systemic metabolic improvement. These integrated effects underscore the unique cardiovascular profile of SGLT2 inhibitors, distinguishing them from conventional glucose-lowering agents.

Evidence from Major Clinical Trials and Outcome Studies

The clinical efficacy of SGLT2 inhibitors has been established through multiple large-scale randomized controlled trials. Cardiovascular outcome trials such as EMPA REG OUTCOME, CANVAS, and DECLARE TIMI 58 demonstrated significant reductions in heart failure hospitalization and cardiovascular mortality among patients with Type 2 diabetes at high cardiovascular risk [17].

Renal outcome trials, including CREDENCE and DAPA CKD, provided compelling evidence of slowed progression of chronic kidney disease, reduced risk of end-stage renal disease, and improved survival [18]. Importantly, these benefits were observed across a broad range of baseline renal function and extended to patients without diabetes.

Heart failure-specific trials, such as DAPA HF and EMPEROR Reduced, confirmed the efficacy of SGLT2 inhibitors in reducing heart failure events irrespective of glycemic status [19]. These findings have reshaped clinical guidelines, positioning SGLT2 inhibitors as foundational therapies in cardiorenal disease management. Collectively, trial data support the consistent and reproducible benefits of SGLT2 inhibitors across diverse populations, reinforcing their role as cornerstone agents in Type 2 diabetes care.

Safety Profile, Limitations, and Emerging Perspectives

While SGLT2 inhibitors are generally well tolerated, their use is associated with specific adverse effects, including genital mycotic infections, volume depletion, and rare cases of diabetic ketoacidosis [20]. Appropriate patient selection, education, and monitoring are essential to minimize these risks.

Limitations of current evidence include underrepresentation of certain populations and limited long-term safety data beyond a decade of use. Ongoing research is exploring novel indications, combination therapies, and potential benefits in non-diabetic kidney and cardiovascular diseases.

Future directions include elucidation of molecular targets responsible for organ protection and identification of biomarkers to predict therapeutic response [21]. These efforts will further refine the clinical application of SGLT2 inhibitors and expand their therapeutic potential.

CONCLUSION

SGLT2 inhibitors have fundamentally altered the management of Type 2 diabetes by demonstrating substantial cardiovascular and renal benefits that extend beyond glucose lowering. Through integrated biochemical, hemodynamic, and metabolic mechanisms, these agents address key pathways involved in the development and progression of diabetic complications. Restoration of renal hemodynamics, improvement in myocardial energy efficiency, reduction of inflammation, and modulation of neurohormonal activity collectively contribute to their protective effects. Robust evidence from randomized clinical trials consistently supports their efficacy in reducing heart failure events, slowing kidney disease progression, and improving survival across diverse patient populations. Despite remaining questions regarding long-term outcomes and optimal patient selection, the overall benefit-to-risk profile of SGLT2 inhibitors is highly favorable. Continued research will further clarify their mechanisms of action and expand their therapeutic scope. It is recommended that SGLT2 inhibitors be incorporated early into the management of Type 2 diabetes in patients at risk of cardiovascular and renal disease to maximize long-term clinical benefit.

REFERENCES

1. Ugwu, O.P.-C., Alum, E.U., Okon, M.B., Aja, P.M., Obeagu, E.I., Onyeneke, E.C.: Ethanol root extract and fractions of *Sphenocentrum jollyanum* abrogate hyperglycaemia and low body weight in streptozotocin-induced diabetic Wistar albino rats. RPS Pharmacy and Pharmacology Reports. 2, rqad010 (2023). https://doi.org/10.1093/rpsppr/rqad010
2. Tangvarasittichai, S.: Oxidative stress, insulin resistance, dyslipidemia and type 2 diabetes mellitus. World J Diabetes. 6, 456–480 (2015). https://doi.org/10.4239/wjd.v6.i3.456
3. Usman, M.S., Khan, M.S., Butler, J.: The Interplay Between Diabetes, Cardiovascular Disease, and Kidney Disease. ADA Clinical Compendia. 2021, 13–18 (2021). https://doi.org/10.2337/db20211-13
4. Brown, E., Rajeev, S.P., Cuthbertson, D.J., Wilding, J.P.H.: A review of the mechanism of action, metabolic profile and haemodynamic effects of sodium-glucose co-transporter-2 inhibitors. Diabetes, Obesity and Metabolism. 21, 9–18 (2019). https://doi.org/10.1111/dom.13650
5. Wilding, J.P.H., Evans, M., Fernando, K., Gorriz, J.L., Cebrian, A., Diggle, J., Hicks, D., sJames, J., Newland-Jones, P., Ali, A., Bain, S., Da Porto, A., Patel, D., Viljoen, A., Wheeler, D.C., Del Prato, S.: The Place and Value of Sodium-Glucose Cotransporter 2 Inhibitors in the Evolving Treatment Paradigm for Type 2 Diabetes Mellitus: A Narrative Review. Diabetes Ther. 13, 847–872 (2022). https://doi.org/10.1007/s13300-022-01228-w
6. Alum, E.U., Krishnamoorthy, R., Gatasheh, M.K., Subbarayan, S., Vijayalakshmi, P., Uti, D.E.: Protective Role of Jimson Weed in Mitigating Dyslipidemia, Cardiovascular, and Renal Dysfunction in Diabetic Rat Models:

In Vivo and *in Silico* Evidence. Natural Product Communications. 19, 1934578X241299279 (2024). https://doi.org/10.1177/1934578X241299279
7. De Nicola, L., Gabbai, F.B., Liberti, M.E., Sagliocca, A., Conte, G., Minutolo, R.: Sodium/Glucose Cotransporter 2 Inhibitors and Prevention of Diabetic Nephropathy: Targeting the Renal Tubule in Diabetes. American Journal of Kidney Diseases. 64, 16–24 (2014). https://doi.org/10.1053/j.ajkd.2014.02.010
8. Szekeres, Z., Toth, K., Szabados, E.: The Effects of SGLT2 Inhibitors on Lipid Metabolism. Metabolites. 11, (2021). https://doi.org/10.3390/metabo11020087
9. Hoong, C.W.S., Chua, M.W.J.: SGLT2 Inhibitors as Calorie Restriction Mimetics: Insights on Longevity Pathways and Age-Related Diseases. Endocrinology. 162, bqab079 (2021). https://doi.org/10.1210/endocr/bqab079
10. Salvatore, T., Galiero, R., Caturano, A., Rinaldi, L., Martino, A.D., Albanese, G., Salvo, J.D., Epifani, R., Marfella, R., Docimo, G., Lettieri, M., Sardu, C., Sasso, F.C.: An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors. International Journal of Molecular Sciences. 23, (2022). https://doi.org/10.3390/ijms23073651
11. Koh, E.S., Kim, G.-H., Chung, S.: Intrarenal Mechanisms of Sodium-Glucose Cotransporter-2 Inhibitors on Tubuloglomerular Feedback and Natriuresis. Endocrinol Metab. 38, 359–372 (2023). https://doi.org/10.3803/EnM.2023.1764
12. Koh, E.S., Kim, G.-H., Chung, S.: Intrarenal Mechanisms of Sodium-Glucose Cotransporter-2 Inhibitors on Tubuloglomerular Feedback and Natriuresis. Endocrinol Metab. 38, 359–372 (2023). https://doi.org/10.3803/EnM.2023.1764
13. Palmer, B.F., Clegg, D.J.: Kidney-Protective Effects of SGLT2 Inhibitors. Clinical Journal of the American Society of Nephrology. 18, 279 (2023). https://doi.org/10.2215/CJN.09380822
14. Low Wang, C.C., Hess, C.N., Hiatt, W.R., Goldfine, A.B.: Clinical Update: Cardiovascular Disease in Diabetes Mellitus. Circulation. 133, 2459–2502 (2016). https://doi.org/10.1161/CIRCULATIONAHA.116.022194
15. Fathi, A., Vickneson, K., Singh, J.S.: SGLT2-inhibitors; more than just glycosuria and diuresis. Heart Fail Rev. 26, 623–642 (2021). https://doi.org/10.1007/s10741-020-10038-w
16. Li, C., Zhang, J., Xue, M., Li, X., Han, F., Liu, X., Xu, L., Lu, Y., Cheng, Y., Li, T., Yu, X., Sun, B., Chen, L.: SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart. Cardiovasc Diabetol. 18, 15 (2019). https://doi.org/10.1186/s12933-019-0816-2
17. Yu, J., Zhou, Z., Mahaffey, K.W., Matthews, D.R., Neuen, B.L., Heerspink, H.J.L., Jardine, M.J., Li, J., Perkovic, V., Neal, B., Arnott, C.: An exploration of the heterogeneity in effects of SGLT2 inhibition on cardiovascular and all-cause mortality in the EMPA-REG OUTCOME, CANVAS Program, DECLARE-TIMI 58, and CREDENCE trials. International Journal of Cardiology. 324, 165–172 (2021). https://doi.org/10.1016/j.ijcard.2020.09.050
18. Larmour, K., Levin, A.: Slowing Progression in CKD. Clin J Am Soc Nephrol. 16, 1117–1119 (2021). https://doi.org/10.2215/CJN.20211220
19. Zannad, F., Ferreira, J.P., Pocock, S.J., Anker, S.D., Butler, J., Filippatos, G., Brueckmann, M., Ofstad, A.P., Pfarr, E., Jamal, W., Packer, M.: SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. The Lancet. 396, 819–829 (2020). https://doi.org/10.1016/S0140-6736(20)31824-9
20. Gorgojo-Martínez, J.J., Górriz, J.L., Cebrián-Cuenca, A., Conde, A.C., Arribas, M.V.: Clinical Recommendations for Managing Genitourinary Adverse Effects in Patients Treated with SGLT-2 Inhibitors: A Multidisciplinary Expert Consensus. Journal of Clinical Medicine. 13, (2024). https://doi.org/10.3390/jcm13216509
21. Joumaa, J.P., Raffoul, A., Sarkis, C., Chatrieh, E., Zaidan, S., Attieh, P., Harb, F., Azar, S., Ghadieh, H.E.: Mechanisms, Biomarkers, and Treatment Approaches for Diabetic Kidney Disease: Current Insights and Future Perspectives. Journal of Clinical Medicine. 14, (2025). https://doi.org/10.3390/jcm14030727

CITE AS: Nakawungu Catherine (2026). SGLT2 Inhibitors in Type 2 Diabetes: Cardiorenal Protection Mechanisms and Clinical Outcomes. NEWPORT INTERNATIONAL JOURNAL OF SCIENTIFIC AND EXPERIMENTAL SCIENCES, 7(2):131-134.
https://doi.org/10.59298/NIJSES/2026/72.131134